Paper11907488
Low daily 10-mg and 20-mg doses of fluvoxamine inhibit the metabolism of both caffeine (cytochrome P4501A2) and omeprazole (cytochrome P4502C19).
Christensen M and 8 others. Clin Pharmacol Ther, 2002. Cited by 77 papers, by iCite.
Cite this record
ConductScience Library. Low daily 10-mg and 20-mg doses of fluvoxamine inhibit the metabolism of both caffeine (cytochrome P4501A2) and omeprazole (cytochrome P4502C19). Papers, record 11907488. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/11907488
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
Topics17
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Adrenergic Agents | Major topic |
| Caffeine | Major topic |
| Central Nervous System Stimulants | Major topic |
| Debrisoquin | Major topic |
| Enzyme Inhibitors | Major topic |
| Fluvoxamine | Major topic |
| Omeprazole | Major topic |
| Selective Serotonin Reuptake Inhibitors | Major topic |
| Adult | |
| Area Under Curve | |
| Cytochrome P-450 CYP1A2 Inhibitors | |
| Dose-Response Relationship, Drug | |
| Drug Interactions | |
| Female | |
| Humans | |
| Male | |
| Middle Aged |
Source PubMed
Grants2
Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.
| Grant, as the record writes it | Agency | Country | NIH project | Stated by | Source |
|---|---|---|---|---|---|
| 1R01 GM60548-01A2 | NIGMS NIH HHS | United States | R01GM605480 | PubMed | NIH RePORTER |
| R01GM060548 | NIH | NIH RePORTER |
Trials1
The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.
| Trial | Title | The trial lists it as | Named in the paper's record |
|---|---|---|---|
| NCT05216614 | Fluvoxamine to Augment Olfactory Recovery For Long COVID-19 Parosmia | Background |
Source ClinicalTrials.gov
Cited by30
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 77 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42234077 | Collecting Metabolite Pharmacokinetics in Drug-Drug Interaction Studies: A Review of Industry Practices and Data Utilization. | Clin Pharmacokinet | 2026 | https://conductscience.org/library/papers/42234077 | PubMed |
| 41247448 | The Impact of Fluvoxamine on Clozapine and Norclozapine Serum Concentrations. | Eur J Drug Metab Pharmacokinet | 2026 | https://conductscience.org/library/papers/41247448 | PubMed |
| 39870954 | An Exploration of the Interplay Between Caffeine and Antidepressants Through the Lens of Pharmacokinetics and Pharmacodynamics. | Eur J Drug Metab Pharmacokinet | 2025 | https://conductscience.org/library/papers/39870954 | PubMed |
| 36946597 | Beyond "Psychotropic": Repurposing Psychiatric Drugs for COVID-19, Alzheimer's Disease, and Cancer. | J Clin Psychiatry | 2023 | https://conductscience.org/library/papers/36946597 | PubMed |
| 36760517 | Polymorphisms in the gene encoding CYP1A2 influence prostate cancer risk and progression. | Oncol Lett | 2023 | https://conductscience.org/library/papers/36760517 | PubMed |
| 36557319 | Optimising Fluvoxamine Maternal/Fetal Exposure during Gestation: A Pharmacokinetic Virtual Clinical Trials Study. | Metabolites | 2022 | https://conductscience.org/library/papers/36557319 | PubMed |
| 35280254 | Pharmacokinetics of Caffeine: A Systematic Analysis of Reported Data for Application in Metabolic Phenotyping and Liver Function Testing. | Front Pharmacol | 2021 | https://conductscience.org/library/papers/35280254 | PubMed |
| 33940506 | Disease-drug and drug-drug interaction in COVID-19: Risk and assessment. | Biomed Pharmacother | 2021 | https://conductscience.org/library/papers/33940506 | PubMed |
| 33363564 | How Can Drug Metabolism and Transporter Genetics Inform Psychotropic Prescribing? | Front Genet | 2020 | https://conductscience.org/library/papers/33363564 | PubMed |
| 33180097 | Fluvoxamine vs Placebo and Clinical Deterioration in Outpatients With Symptomatic COVID-19: A Randomized Clinical Trial. | JAMA | 2020 | https://conductscience.org/library/papers/33180097 | PubMed |
| 29569723 | Cytochrome P450 3A Induction Predicts P-glycoprotein Induction; Part 1: Establishing Induction Relationships Using Ascending Dose Rifampin. | Clin Pharmacol Ther | 2018 | https://conductscience.org/library/papers/29569723 | PubMed |
| 27437087 | Inhibition of Cytochrome P450 by Propolis in Human Liver Microsomes. | Toxicol Res | 2016 | https://conductscience.org/library/papers/27437087 | PubMed |
| 26936044 | Quantitative Prediction of Drug Interactions Caused by CYP1A2 Inhibitors and Inducers. | Clin Pharmacokinet | 2016 | https://conductscience.org/library/papers/26936044 | PubMed |
| 23023659 | Psychotropic drug-drug interactions involving P-glycoprotein. | CNS Drugs | 2012 | https://conductscience.org/library/papers/23023659 | PubMed |
| 20582584 | Pharmacogenetic testing and therapeutic drug monitoring are complementary tools for optimal individualization of drug therapy. | Eur J Clin Pharmacol | 2010 | https://conductscience.org/library/papers/20582584 | PubMed |
| 19902987 | Polymorphism of human cytochrome P450 2D6 and its clinical significance: part II. | Clin Pharmacokinet | 2009 | https://conductscience.org/library/papers/19902987 | PubMed |
| 18224311 | Estimation of the area under the concentration-time curve of racemic lansoprazole by using limited plasma concentration of lansoprazole enantiomers. | Eur J Clin Pharmacol | 2008 | https://conductscience.org/library/papers/18224311 | PubMed |
| 17596106 | Effect of fluvoxamine on the pharmacokinetics of roflumilast and roflumilast N-oxide. | Clin Pharmacokinet | 2007 | https://conductscience.org/library/papers/17596106 | PubMed |
| 17471183 | Tricyclic antidepressant pharmacology and therapeutic drug interactions updated. | Br J Pharmacol | 2007 | https://conductscience.org/library/papers/17471183 | PubMed |
| 16944962 | Therapeutic drug monitoring and pharmacogenetic tests as tools in pharmacovigilance. | Drug Saf | 2006 | https://conductscience.org/library/papers/16944962 | PubMed |
Genes3
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes | Source |
|---|---|---|---|---|
| CYP1A2 | 1544 | PubTator's text mining | https://conductscience.org/library/genes/1544 | NCBI Gene |
| CYP2C19 | 1557 | PubTator's text mining | https://conductscience.org/library/genes/1557 | NCBI Gene |
| CYP2D6 | 1565 | PubTator's text mining | https://conductscience.org/library/genes/1565 | NCBI Gene |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Comments and corrections
- References
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/11907488
GET https://conductscience.org/api/papers/v1/11907488/cited_by?page=2